Discontinuations for adverse events were consistently low, ranging from 2.5% to 10.4%.
INTRODUCTION
In the last decade, there has been considerable change in the number and type of pharmacotherapies available for type 2 diabetes. One of the most significant advances has been an improved understanding of the incretin effect and its role in the pathophysiology of type 2 diabetes, which has led to the development of a number of new glucose-lowering agents within the incretin class [1] . Both glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP4) inhibitors are now licensed and used routinely in the management of type 2 diabetes [1] . Given the positive impact of GLP-1R agonists on a number of the pathophysiological traits of type 2 diabetes, including clinically significant reductions in body weight, this class of drug continues to expand with new analogs in development [1] .
Currently, four GLP-1R agonists-exenatide (both as a twice-daily (BD) and once-weekly (QW) long-acting release (LAR) formulation), liraglutide, and lixisenatide-are available as treatments for type 2 diabetes (Fig. 1) . Exenatide is an identical synthetic version of exendin-4, a GLP-1-like peptide isolated from the saliva of the Gila monster lizard Heloderma suspectum that exhibits 53% amino acid identity with human GLP-1 and is a potent agonist of the human GLP-1R [2] . Exenatide has a terminal half-life of *2.4 h and is administered BD subcutaneously [3] . A long-acting release formulation, exenatide-LAR, delivers the drug in microspheres of a biodegradable polymer resulting in a prolonged half-life and allowing once-weekly administration, is also approved [4] . This formulation has been shown to provide better glycemic control than conventional exenatide BD over 52 weeks [5] .
Liraglutide is an analog of human GLP-1, modified by a Ser34Arg amino acid substitution and with the addition of a Glu-spaced fatty acid chain through the e-amino group of Lys at position 26 [1] . These modifications alter the tertiary structure of the molecule, stabilizing liraglutide against DPP-4 degradation and allowing it to self-associate and reversibly bind to serum albumin, creating a circulating reservoir of drug [1] . These changes result in decreased clearance and protracted activity, with a half-life of 13 h suitable for once-daily (OD) subcutaneous administration [6] .
Liraglutide was approved for clinical use in Europe in 2009 and in the USA in 2010.
Lixisenatide (AVE0010) is the fourth GLP-1R
agonist to be licensed for the treatment of type 2 diabetes. Like exenatide, the 44-amino acid peptide is based on the structure of exendin-4, with modifications consisting of a deletion of a proline residue and addition of six lysine residues at the C terminal ( Fig. 2 ) [7] . The in vivo half-life of lixisenatide (20 lg OD) is 3 h [8] . Lixisenatide OD is indicated for the treatment of adults with type 2 diabetes to achieve glycemic control in combination with oral glucose-lowering drugs and/or basal insulin when these, together with diet and exercise, do not provide adequate glycemic control. Although these GLP-1R agonists act through the same receptor, differences in their pharmacokinetics-namely short-acting or Mono-Japan) [13] . In addition, the efficacy and safety profile of lixisenatide in combination with basal insulin was assessed in three randomised trials [14] [15] [16] . More than 5,000 patients were recruited in the GetGoal studies worldwide. In three trials, one-or two-step dose increases up to the 20 lg OD treatment dose were compared [13, 17, 18] , and in one trial, morning and evening dosing of lixisenatide were compared [19] . In the majority of studies, patients received metformin, reflecting the current recommendation for metformin by NICE and the American Diabetes Association/ European Association for the Study of Diabetes (ADA/EASD) as first-line therapy [23, 24] . Data from the 11 GetGoal trials have been published, or presented at international conferences (summarized in Table 1 ).
Lixisenatide Monotherapy
GetGoal-Mono was a 12-week, double-blind, placebo-controlled trial that randomised 361 patients with type 2 diabetes of mean duration 1.1-1.4 years attempting to control their diabetes with diet and exercise alone, to lixisenatide OD for 12 weeks as a one-step dose increase (10 lg for 2 weeks, then 20 lg) or twostep dose increase (10 lg for 1 week, 15 lg for 1 week, then 20 lg), or placebo also with a oneor two-step increase [17] . HbA 1c was improved in both dose escalation groups compared with placebo, with a numerically larger reduction in those with a single-dose increase (least squares mean reduction of 0.66% with one-step and 0.54% with two-step, p\0.0001). Lixisenatide OD was well tolerated; the most frequent adverse events were gastrointestinal (mainly nausea with low rates of vomiting and diarrhea) [17] . The rates of nausea and of discontinuation because of adverse events were similar with the two-step and one-step dose increases. Average body weight reductions of 2 kg were reported in both lixisenatide and placebo groups, reflecting a marked placebo effect in some patients receiving an inactive injection.
In GetGoal-Mono Japan, Japanese patients experienced a 0.74% and 0.99% reduction in HbA 1c (one-step or two-step dose increase, respectively) at week 24, which was sustained at week 76 (reduction of 0.72% across both groups) from a baseline HbA 1c of 66 mmol/mol (8.2%). This small, open-label safety study performed for the regulatory authorities in Japan reported nausea as the most commonly reported adverse event, with no new safety signals observed [13] .
Patients Inadequately Controlled on Metformin
GetGoal-M assessed the efficacy and safety of morning or evening injections of lixisenatide in for two-step and -0.6% for combined placebo). no severe hypoglycemic events were reported. In the extension study, the most frequently reported AEs were nausea and vomiting, with few discontinuations. Symptomatic hypoglycemia remained uncommon (3.7-7.5%), with a similar proportion of patients with events in the placebo arm (7.5%). These findings suggested that the one-step dose increase was appropriate for treatment initiation [18] .
In the open-label GetGoal-X study, 639 patients with type 2 diabetes inadequately 13.0% with exenatide), and fewer premature discontinuations overall with lixisenatide (12.9% vs. 14.2% with exenatide). [21] . Of note, the study enrolled a different ethnic mix to most other GetGoal studies with 45% of patients being of Asian origin. Higher rates of nausea and vomiting with lixisenatide were recorded compared with placebo. Symptomatic hypoglycemia was not different between lixisenatide and placebo (15.3% vs. 12.3%; p = NS) [21] .
Patients Inadequately Controlled on Thiazolidinediones
GetGoal-P assessed the addition of lixisenatide to therapy in patients inadequately controlled on C30 mg/day of pioglitazone (with or without metformin) [22] . A total of 484 patients with a mean duration of diabetes of 8.1 years were randomised to receive lixisenatide 20 lg OD (n = 323) or placebo (n = 161) with a two-step dose increase, in combination with pioglitazone, for the main double-blind treatment period of 24 weeks, followed by a variable double-blind extension of at least 52 weeks. Around 81% of patients were using metformin at screening.
Lixisenatide significantly reduced HbA 1c from baseline to week 24 compared with placebo (LS mean reduction of -0.90% vs.
-0.34%; p\0.0001) and significantly greater proportions of patients receiving lixisenatide achieved HbA 1c goals of B48 mmol/mol (6.5%) and \53 mmol/mol (7.0%) compared with placebo [22] . Efficacy was maintained in the extension period (HbA 1c reduced by 1.1% (lixisenatide) and 0.6% (placebo) at week 76).
Lixisenatide significantly improved FPG levels. There was no significant reduction in body weight compared with placebo. Significantly fewer lixisenatide-treated patients required rescue therapy compared with placebo-treated patients. Lixisenatide was well tolerated with similar rates of symptomatic hypoglycemia in both groups (3.4% with lixisenatide vs. 1.2% with placebo) [22] . This study demonstrated that the addition of lixisenatide to pioglitazone therapy significantly improved glycemic control with a low risk of hypoglycemia and good tolerability.
Patients Inadequately Controlled on Basal Insulin
GetGoal-L-Asia randomised 311 patients with long-duration diabetes (mean 13.9 years) who were inadequately controlled on basal insulin to lixisenatide 20 lg OD (n = 154), or placebo (n = 157) for 24 weeks [14] . All patients continued treatment throughout the study with their established doses of basal insulin with or without SU. Approximately 70% of patients were receiving an SU at screening. Around 60% of patients were receiving insulin glargine, 27% were receiving insulin detemir and 13% were receiving NPH insulin [14] . This study was conducted in Japan, GetGoal-L randomised 496 patients inadequately controlled on basal insulin and metformin to lixisenatide 20 lg OD or placebo for 24 weeks with a double-blind extension of at least 52 weeks [15] . Patients were randomised in a 2:1 ratio to lixisenatide (n = 329) or placebo (n = 167). The mean duration of diabetes was approximately 12.5 years, and 79% of patients were using metformin at screening. Patients had been receiving basal insulin for 3.1 years on average, with 50% taking insulin glargine and the majority of the remainder taking NPH Although the FDA has no requirement for the investigational drug to show superiority to placebo, ELIXA is designed to demonstrate that lixisenatide reduces cardiovascular morbidity and mortality in patients with type 2 diabetes who have recently experienced an acute coronary syndrome event. Patients have been randomised, double-blind, to receive lixisenatide 20 lg OD or placebo. This eventdriven study has an estimated enrollment of 6,000 patients and will run until the last patient has been followed up for at least 10 months; the median follow-up is estimated to be nearly 2 years. The primary endpoint is the time to the first occurrence of a primary cardiovascular event (the composite of cardiovascular death, (Table 2 ). These reductions appear slightly lower than those reported with liraglutide, which may reflect differences in baseline characteristics, including HbA 1c , or differences in pharmacodynamics such as the more pronounced effect that long-acting GLP-1R agonists exert on FPG [9] ; however, it is difficult to make indirect comparisons across studies. The randomised comparison of lixisenatide OD with exenatide BD showed lixisenatide was non-inferior to exenatide and with similar numbers of patients achieving target HbA 1c of 53 mmol/mol (7%) (around a half in each treatment group) [12] , but this was achieved with threefold fewer symptomatic hypoglycemic events and with better gastrointestinal tolerability than exenatide BD.
Discontinuations for adverse events were consistently low, ranging from 2.5% to 10.4% across the program (Table 3) .
Except for GetGoal-Mono Japan, the GetGoal studies were 12-24 weeks in duration with longer, safety-orientated study extensions of at least 1 year planned in six trials (GetGoal-F1, -M, -X, -S, -P and -L). Long-term efficacy data reported so far (from GetGoal-P and GetGoal-F1) suggest that the glycemic improvement with lixisenatide is maintained, with good tolerability during long-term treatment and no increased hypoglycemia risk versus placebo [18, 22] .
Lixisenatide treatment had a consistent, pronounced effect on PPG [14] [15] [16] [17] [18] 21] , reflecting the rapid increase in plasma levels after injection that leads to delayed gastric emptying and delayed systemic glucose absorption, which manifest as blunted postmeal glucose excursions [9] . Long-acting GLP-1R agonists do not reduce PPG to the same extent and do not exert the same effect on gastric motility after long-term use as shortacting agonists [9] . Studies of gastric emptying suggest that long-acting agonists are subject to desensitization/tachyphylaxis of the effect, whereas short-acting agonists such as lixisenatide continue to inhibit gastric emptying even after repeated dosing [9] . The 
CONCLUSION
Lixisenatide is the latest addition to the GLP-1R agonist class of treatments for type 2 diabetes.
Although the fourth agent to be licensed, its distinct pharmacodynamic action with marked effects on PPG supports the effective glycemic management of patients with inadequate control on basal insulin, an approach that has been validated in three phase III clinical trials. This, coupled with patient-centric propertiesonce-daily dosing, a one-step increase to a single maintenance dose, and a lower acquisition cost-suggest lixisenatide is an important additional treatment option in type 2 diabetes. 
